The stock of Protagonist Therapeutics Inc (PTGX) has gone up by 0.57% for the week, with a -11.19% drop in the past month and a -21.64% drop in the past quarter. The volatility ratio for the week is 4.87%, and the volatility levels for the past 30 days are 4.24% for PTGX. The simple moving average for the past 20 days is -4.36% for PTGX’s stock, with a -2.84% simple moving average for the past 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio of 13.81x that is above its average ratio. Additionally, the 36-month beta value for PTGX is 2.23. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PTGX is 56.09M and currently, short sellers hold a 6.77% ratio of that float. The average trading volume of PTGX on January 20, 2025 was 670.57K shares.
PTGX) stock’s latest price update
Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has plunge by 0.77relation to previous closing price of 36.54. Nevertheless, the company has seen a 0.57% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-13 that Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Goldman repeating the rating for PTGX by listing it as a “Neutral.” The predicted price for PTGX in the upcoming period, according to Goldman is $47 based on the research report published on December 06, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $62. The rating they have provided for PTGX stocks is “Outperform” according to the report published on December 06th, 2024.
Wedbush gave a rating of “Outperform” to PTGX, setting the target price at $58 in the report published on November 05th of the previous year.
PTGX Trading at -10.38% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.69% of loss for the given period.
Volatility was left at 4.24%, however, over the last 30 days, the volatility rate increased by 4.87%, as shares sank -9.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.26% lower at present.
During the last 5 trading sessions, PTGX rose by +0.57%, which changed the moving average for the period of 200-days by +31.55% in comparison to the 20-day moving average, which settled at $38.50. In addition, Protagonist Therapeutics Inc saw -4.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from MOLINA ARTURO MD, who sale 26,000 shares at the price of $44.70 back on Nov 27 ’24. After this action, MOLINA ARTURO MD now owns 46,444 shares of Protagonist Therapeutics Inc, valued at $1,162,280 using the latest closing price.
MOLINA ARTURO MD, the Chief Medical Officer of Protagonist Therapeutics Inc, sale 5,529 shares at $45.60 during a trade that took place back on Nov 26 ’24, which means that MOLINA ARTURO MD is holding 46,444 shares at $252,122 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.53. The total capital return value is set at 0.27. Equity return is now at value 40.97, with 36.59 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 21.13. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 64.94.
Currently, EBITDA for the company is -90.34 million with net debt to EBITDA at -0.79. When we switch over and look at the enterprise to sales, we see a ratio of 6.41. The receivables turnover for the company is 121.32for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.70.
Conclusion
In conclusion, Protagonist Therapeutics Inc (PTGX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
